Search Results - "COLEMAN, Morton"

Ibrutinib Resistance in Chronic Lymphocytic Leukemia by Furman, Richard R, Cheng, Shuhua, Lu, Pin, Setty, Menu, Perez, Alexendar R, Guo, Ailin, Racchumi, Joelle, Xu, Guozhou, Wu, Hao, Ma, Jiao, Steggerda, Susanne M, Coleman, Morton, Leslie, Christina, Wang, Y. Lynn

“…Ibrutinib, a Bruton's tyrosine kinase inhibitor, is active in CLL, but resistance may emerge. The authors observed the emergence of a CLL clone with a…”
Get full text

Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia by Rogers, Kerry A., Thompson, Philip A., Allan, John N., Coleman, Morton, Sharman, Jeff P., Cheson, Bruce D., Jones, Daniel, Izumi, Raquel, Frigault, Melanie M., Quah, Cheng, Raman, Rakesh K., Patel, Priti, Wang, Min Hui, Kipps, Thomas J.

“…B-cell receptor signalling inhibition by targeting Bruton tyrosine kinase (BTK) is effective in treating chronic lymphocytic leukemia (CLL). The BTK inhibitor…”
Get full text

Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma by Ruan, Jia, Martin, Peter, Christos, Paul, Cerchietti, Leandro, Tam, Wayne, Shah, Bijal, Schuster, Stephen J., Rodriguez, Amelyn, Hyman, David, Calvo-Vidal, Maria Nieves, Smith, Sonali M., Svoboda, Jakub, Furman, Richard R., Coleman, Morton, Leonard, John P.

“…We report 5-year follow-up of a multicenter phase 2 study of lenalidomide plus rituximab (LR) as initial treatment of mantle cell lymphoma (MCL). The regimen…”
Get full text

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial by O'Brien, Susan, Prof, Furman, Richard R, MD, Coutre, Steven E, Prof, Sharman, Jeff P, MD, Burger, Jan A, MD, Blum, Kristie A, MD, Grant, Barbara, MD, Richards, Donald A, MD, Coleman, Morton, Prof, Wierda, William G, MD, Jones, Jeffrey A, MD, Zhao, Weiqiang, MD, Heerema, Nyla A, Prof, Johnson, Amy J, PhD, Izumi, Raquel, PhD, Hamdy, Ahmed, MD, Chang, Betty Y, PhD, Graef, Thorsten, MD, Clow, Fong, ScD, Buggy, Joseph J, PhD, James, Danelle F, MD, Byrd, John C, Prof

“…Summary Background Chemoimmunotherapy has led to improved numbers of patients achieving disease response, and longer overall survival in young patients with…”
Get full text

Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma by JIA RUAN, MARTIN, Peter, CHADBURN, Amy, CESARMAN, Ethel, COLEMAN, Morton, LEONARD, John P, FURMAN, Richard R, LEE, Shing M, CHEUNG, Ken, VOSE, Julie M, LACASCE, Ann, MORRISON, Julia, ELSTROM, Rebecca, ELY, Scott

“…The proteasome inhibitor bortezomib may enhance activity of chemoimmunotherapy in lymphoma. We evaluated dose-escalated bortezomib plus standard…”
Get full text

Characterization of ibrutinib‐sensitive and ‐resistant mantle lymphoma cells by Ma, Jiao, Lu, Pin, Guo, Ailin, Cheng, Shuhua, Zong, Hongliang, Martin, Peter, Coleman, Morton, Wang, Y. Lynn

“…Summary Ibrutinib inhibits Bruton tyrosine kinase (BTK), a key component of early B‐cell receptor (BCR) signalling pathways. A multicentre phase 2 trial of…”
Get full text

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma by Berenson, James R., Cartmell, Alan, Bessudo, Alberto, Lyons, Roger M., Harb, Wael, Tzachanis, Dimitrios, Agajanian, Richy, Boccia, Ralph, Coleman, Morton, Moss, Robert A., Rifkin, Robert M., Patel, Priti, Dixon, Sandra, Ou, Ying, Anderl, Janet, Aggarwal, Sanjay, Berdeja, Jesus G.

“…Carfilzomib, a proteasome inhibitor, is approved in the United States as a single agent, and in combination with dexamethasone or lenalidomide/dexamethasone…”
Get full text

The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale by Gallamini, Andrea, Barrington, Sally F, Biggi, Alberto, Chauvie, Stephane, Kostakoglu, Lale, Gregianin, Michele, Meignan, Michel, Mikhaeel, George N, Loft, Annika, Zaucha, Jan M, Seymour, John F, Hofman, Michael S, Rigacci, Luigi, Pulsoni, Alessandro, Coleman, Morton, Dann, Eldad J, Trentin, Livio, Casasnovas, Olivier, Rusconi, Chiara, Brice, Pauline, Bolis, Silvia, Viviani, Simonetta, Salvi, Flavia, Luminari, Stefano, Hutchings, Martin

“…A retrospective, international, multicenter study was undertaken to assess: (i) the prognostic role of 'interim' positron emission tomography performed during…”
Get full text

Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma by MARTIN, Peter, CHADBURN, Amy, MELNICK, Ari, KNOWLES, Daniel M, CHEN-KIANG, Selina, COLEMAN, Morton, LEONARD, John P, CHRISTOS, Paul, WEIL, Karen, FURMAN, Richard R, JIA RUAN, ELSTROM, Rebecca, NIESVIZKY, Ruben, ELY, Scott, DILIBERTO, Maurizio

“…Treatment of mantle-cell lymphoma (MCL) is nonstandardized, though patients are commonly treated immediately at diagnosis. Because data on observation, or…”
Get full text

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma by Ruan, Jia, Martin, Peter, Shah, Bijal, Schuster, Stephen J., Smith, Sonali M., Furman, Richard R., Christos, Paul, Rodriguez, Amelyn, Svoboda, Jakub, Lewis, Jessica, Katz, Orel, Coleman, Morton, Leonard, John P.

Get full text

Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results by MORSCHHAUSER, Franck, LEONARD, John P, WEGENER, William A, GOLDENBERG, David M, FAYAD, Luis, COIFFIER, Bertrand, PETILLON, Marie-Odile, COLEMAN, Morton, SCHUSTER, Stephen J, DYER, Martin J. S, HORNE, Heather, TEOH, Nick

“…This is a multicenter phase I/II dose-finding study in relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL) evaluating veltuzumab, a humanized anti-CD20…”
Get full text

FDG‐PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease by Kostakoglu, Lale, Goldsmith, Stanley J., Leonard, John P., Christos, Paul, Furman, Richard R., Atasever, Tamer, Chandramouly, Angely, Verma, Sumeet, Kothari, Pratichi, Coleman, Morton

“…BACKGROUND. Early prediction of response to therapy may offer the potential to identify patients who will benefit from standard conventional therapy. The…”
Get full text

MAGE-A Inhibits Apoptosis in Proliferating Myeloma Cells through Repression of Bax and Maintenance of Survivin by NARDIELLO, Tricia, JUNGBLUTH, Achim A, PEARSE, Roger, COLEMAN, Morton, JAYABALAN, David S, BHARDWAJ, Nina, OLD, Lloyd J, CHEN-KIANG, Selina, HEARN JAY CHO, MEI, Anna, DILIBERTO, Maurizio, XIANGAO HUANG, DABROWSKI, Ania, ANDRADE, Valéria C. C, WASSERSTRUM, Rebecca, ELY, Scott, NIESVIZKY, Ruben

“…The type I Melanoma Antigen GEnes (MAGEs) are commonly expressed in cancers, fueling speculation that they may be therapeutic targets with oncogenic potential…”
Get full text

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma by Niesvizky, Ruben, Jayabalan, David S., Christos, Paul J., Furst, Jessica R., Naib, Tara, Ely, Scott, Jalbrzikowski, Jessica, Pearse, Roger N., Zafar, Faiza, Pekle, Karen, LaRow, April, Lent, Richard, Mark, Tomer, Cho, Hearn J., Shore, Tsiporah, Tepler, Jeffrey, Harpel, John, Schuster, Michael W., Mathew, Susan, Leonard, John P., Mazumdar, Madhu, Chen-Kiang, Selina, Coleman, Morton

“…This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and dexamethasone (BiRD) as…”
Get full text

Pediatric oral Epstein-Barr virus associated self-remitting CD30+ lymphoproliferative disorder: A distinct entity by Schwartz, Ziv, Bowe, Robert B., Coleman, Morton, Magro, Cynthia M.

“…Epstein-Barr virus (EBV) has a well-known association with lymphoproliferative disorders of B and T cell origin. EBV-related B cell lymphoproliferative…”
Get full text

Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma by Reiss, Jonathan, Link, Brian, Ruan, Jia, Furman, Richard, Coleman, Morton, Leonard, John, Martin, Peter

“…Existing data suggest that myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) peak in incidence 5-10 years following exposure to ionizing…”
Get full text

Tositumomab and Iodine-131 Tositumomab Produces Durable Complete Remissions in a Subset of Heavily Pretreated Patients With Low-Grade and Transformed Non-Hodgkin’s Lymphomas by FISHER, Richard I, KAMINSKI, Mark S, WAHL, Richard L, KNOX, Susan J, ZEIENETZ, Andrew D, VOSE, Julie M, LEONARD, John P, KROLL, Stewart, GOLDSMITH, Stanley J, COLEMAN, Morton

“…This study is an integrated efficacy analysis of the five clinical trials of tositumomab and iodine-131 tositumomab in patients with relapsed or refractory…”
Get full text

Severe Hepatotoxicity due to Ibrutinib with a Review of Published Cases by Tafesh, Zaid H., Coleman, Morton, Fulmer, Clifton, Nagler, Jerry

“…Ibrutinib, an irreversible Bruton’s tyrosine kinase inhibitor, is an effective treatment for Waldenström’s macroglobulinemia, chronic lymphocytic leukemia, and…”
Get full text

Monoclonal gammopathy of undetermined significance: a consensus statement by Berenson, James R., Anderson, Kenneth C., Audell, Robert A., Boccia, Ralph V., Coleman, Morton, Dimopoulos, Meletios A., Drake, Matthew T., Fonseca, Rafael, Harousseau, Jean‐Luc, Joshua, Douglas, Lonial, Sagar, Niesvizky, Ruben, Palumbo, Antonio, Roodman, G. David, San‐Miguel, Jesus F., Singhal, Seema, Weber, Donna M., Zangari, Maurizio, Wirtschafter, Eric, Yellin, Ori, Kyle, Robert A.

“…Summary On February 25, 2009, a panel of international experts on plasma cell dyscrasia and skeletal disease met to discuss monoclonal gammopathy of…”
Get full text

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma by Niesvizky, Ruben, Richardson, Paul G., Rajkumar, S. Vincent, Coleman, Morton, Rosiñol, Laura, Sonneveld, Pieter, Schuster, Michael W., Irwin, David, Stadtmauer, Edward A., Facon, Thierry, Harousseau, Jean‐Luc, Boral, Anthony L., Esseltine, Dixie‐Lee, Anderson, Kenneth C., Bladé, Joan

“…Summary Quality of response is associated with prolonged overall survival (OS) in newly diagnosed multiple myeloma patients. This cohort study within the phase…”
Get full text